Small Molecules

13 Jan 2017 Shionogi Announces Positive Top-Line Results For Cefiderocol Pivotal cUTI Clinical Trial
13 Jan 2017 Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis
12 Jan 2017 European Commission Grants Marketing Authorization for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection
11 Jan 2017 Valeant Pharmaceuticals Announces Results Of Second Phase 3 Study For Psoriasis Treatment IDP-118
11 Jan 2017 IACTA Pharmaceuticals Licenses NM133 from Nanomerics for Treatment of Dry Eye
11 Jan 2017 Debiopharm International SA Announces positive Phase 2 Clinical Trial with Debio 1450 in ABSSSI patients
10 Jan 2017 Chi-Med Initiates HMPL-523 Clinical Trials in Hematological Cancer in China
09 Jan 2017 Galmed Pharmaceuticals Completes Patient Recruitment for ARREST Phase IIb NASH study
09 Jan 2017 ORYZON Announces First Patient Dosed in Phase 1 Trial of the LSD1 inhibitor RG6016 in Small Cell Lung Cancer (SCLC)
09 Jan 2017 Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) for Chronic Hepatitis C Achieved High SVR[12] Rates in Genotype 1 Japanese Patients
09 Jan 2017 Tricida Announces Positive Topline Phase 1/2 Clinical Trial Results for TRC101 in 135 Subjects with Chronic Kidney Disease and Metabolic Acidosis
09 Jan 2017 NeuroGenetic Pharmaceuticals Completes Phase 1 Clinical Trials for NGP 555 to Treat and Prevent Alzheimer’s Disease; Shown as Safe and Well-Tolerated in Healthy Volunteers
09 Jan 2017 Lexicon Begins Phase 1 Clinical Trial Of Locally-acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of Diabetes
09 Jan 2017 Aralez Submits Marketing Authorization Application To The European Medicines Agency For PA10040
09 Jan 2017 Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study of Glutaminyl Cyclase Inhibitor PQ912 in early Alzheimer's disease patients
07 Jan 2017 DS Biopharma (DS) Announces that Recruitment has Begun in Two Separate Phase 2b Atopic Dermatitis Studies with Lead Compound DS107 as well as the Successful Completion of a Phase 1 Trial for Follow on Compound DS109
07 Jan 2017 Phenex receives 100 M USD Milestone Payment from Gilead
07 Jan 2017 CalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor
07 Jan 2017 Menlo Therapeutics Starts Enrollment in Two Phase 2 Studies for Pruritus Associated with Atopic Dermatitis and Pruritus Following Burn Injury
07 Jan 2017 Rgenix Announces Treatment of First Patient in Phase 1 Trial of RGX-104, its Lead Immuno-Oncology Therapeutic
06 Jan 2017 Mirati Therapeutics Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs
05 Jan 2017 Otonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO® in Patients with Acute Otitis Externa
05 Jan 2017 Enterome Starts Phase I Clinical Trial With its Lead Candidate EB8018 to Treat Crohn's Disease
05 Jan 2017 Keystone Nano Announces FDA Approval Of Investigational New Drug Application For Ceramide NanoLiposome For The Improved Treatment Of Cancer
05 Jan 2017 Heron Therapeutics Announces Positive Topline Results From Phase 2 Clinical Trial of HTX-011 in Abdominoplasty

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing